3D-Leuko-TAD
| project details | |
|---|---|
|
Acronym |
3D-Leuko-TAD
|
|
Title |
Topologically Associating Domains (TADs) boundary disruption and 3D genome alterations as targets in acute leukemia therapies
|
|
Duration |
Jun 2025 – May 2028 |
|
GA Number |
under preparation
|
|
Programme |
EP PerMed
|
|
Action type |
JTC2024
|
|
Call |
EP PerMed JTC2024: Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets)
|
|
Field |
|
|
Coordinator |
IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”
|
|
Description
|
The “3D-Leuko-TAD” project aims to improve treatments for acute leukemias (acute lymphoblastic and myeloid leukemia) by focusing on how changes in tridimensional structures impact the development of the disease. SHINE leads the stakeholder engagement, communication and dissemination activities (WP7), with some involvement in the ethical framework and considerations (T1.3), and almost no involvement in the other WPs.
|
|
Website |
under preparation |
|
Social Media |
under preparation |
|
Partners |
|